184P - Distribution of genomically defined recurrence risk in luminal A and B breast tumors defined by inmunohistochemistry: a retrospective study in Span...

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Breast Cancer, Early Stage
Breast Cancer
Pathology/Molecular Biology
Presenter Sara Perez Ramirez
Citation Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362
Authors S. Perez Ramirez1, M. del Monte-Millán2, S. López-Tarruella2, I. Márquez-Rodas2, Y. Jerez2, F. Lobo Samper3, Y. Izarzugaza Peron3, N. Martínez Jañez4, J.A. García-Saenz5, F. Moreno Antón5, P. Zamora Auñón6, M. Arroyo Yustos7, M.Á. Lara Álvarez8, E.M. Ciruelos Gil9, L. Manso Sánchez9, M.J. Echarri González10, J.A. Guerra Martínez11, C. Jara Sánchez12, V. Valentín Maganto13, M. Martin Jimenez14
  • 1Medical Oncology, Hospital General Universitario Gregorio Marañon. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28007 - Madrid/ES
  • 2Medical Oncology, Hospital General Universitario Gregorio Marañon. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid/ES
  • 3Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid/ES
  • 4Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid/ES
  • 5Medical Oncology, Hospital Universitario Clínico San Carlos, Madrid/ES
  • 6Medical Oncology, Hospital Universitario La Paz, Madrid/ES
  • 7Medical Oncology, Hospital Universitario Príncipe de Asturias, Madrid/ES
  • 8Medical Oncology, Hospital Universitario Infanta Leonor, Madrid/ES
  • 9Medical Oncology, Hospital Universitario 12 de Octubre, Madrid/ES
  • 10Medical Oncology, Hospital Universitario Severo Ochoa, Madrid/ES
  • 11Medical Oncology, Hospital Universitario de Fuenlabrada, Madrid/ES
  • 12Medical Oncology, Hospital Universitario Fundación Alcorcón, Universidad Rey Juan Carlos, Madrid/ES
  • 13Former Regional Oncology Coordinator, Ministry of Health, Madrid/ES
  • 14Medical Oncology, Hospital General Universitario Gregorio Marañon. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid/ES

Abstract

Background

Semiquantitative inmunohistochemical (IHC) expression of progesterone receptor (PR) adds prognostic value to the current IHC-based luminal A (LA) definition, such that patients (pts) with LA (Ki67  20%) tumors can be spared from adjuvant chemotherapy (CT). Oncotype Dx® (ODX) and MammaPrint® (MP) assays have been validated as predictors of CT benefit. This study assessed the distribution of recurrence risk in LA and LB breast tumors as defined by Ki67 and PR.

Methods

A retrospective analysis was performed in 889 T1-2, N0-Nmic, M0 tumors for which ODX or MP results and local pathology data were available. Ki67 was assessed by IHC (high ≥14% and low 20%). Histological grade was defined using the Nottingham grading system.

Results

Median age 54 years (18-77). All pts had HER2 negative tumors. Median tumor size 15 mm (2-88). Three hundred (33.7%) tumors were classified as LA and 589 (66.3%) as LB. Grade 1 tumors were higher in LA (27%) than in LB (19%) pts (p 

Conclusions

There is a wide distribution of recurrence risk results between LA and LB tumors defined by Ki67 and PR which confirms the important role of gene-expression assays in adjuvant decision making. Of note about half of pts with LB tumors had low recurrence risk indicating minimal benefit from adjuvant CT.

Clinical trial identification

Legal entity responsible for the study

Ministry of Health of the Community of Madrid (Spain)

Funding

Ministry of Health of the Community of Madrid (Spain)

Disclosure

S. López-Tarruella: Advisory role: Novartis, Pfizer, Celgene. Honoraria/lecturer: Novartis, Pfizer, AstraZeneca, Celgene, Roche. I. Márquez-Rodas: Advisory role: Bristol-Myers Squibb, MSD, Novartis, Roche, Pierre Fabre, Amgen and Bioncotech. M. Martin Jimenez: Holds a patent on the predictive value of the PAM50 gene profile assay. All other authors have declared no conflicts of interest.